Trial · NCT03103919
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline to Visit 2 in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Motor Score | Baseline (Visit 1/Week 1) to Visit 2 (Week 12/ 3 months after start of treatment with Neupro) | The Full Analysis Set (FAS) included all subjects who had at least 1 valid Baseline and at least 1 valid post-Baseline efficacy measurement. | Scores on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Finger Tapping Speed Score | Baseline (Visit 1/Week 1) to Visit 2 (Week 12) | The Full Analysis Set (FAS) included all subjects who had at least 1 valid Baseline and at least 1 valid post-Baseline efficacy measurement. | Scores on scale | LEAST_SQUARES_MEAN |
| PRIMARY | Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Rest Tremor Score | Baseline (Visit 1/Week 1) to Visit 2 (Week 12) | The Full Analysis Set (FAS) included all subjects who had at least 1 valid Baseline and at least 1 valid post-Baseline efficacy measurement. | Scores on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Averaged Finger Tapping Speed and Resting Tremor Scores | Baseline (Visit 1/Week 1) to Visit 2 (Week 12) | The Full Analysis Set (FAS) included all subjects who had at least 1 valid Baseline and at least 1 valid post-Baseline efficacy measurement. | Scores on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Postural Tremor Score | Baseline (Visit 1/Week 1) to Visit 2 (Week 12) | The Full Analysis Set (FAS) included all subjects who had at least 1 valid Baseline and at least 1 valid post-Baseline efficacy measurement. | Scores on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Finger Tapping Amplitude Score | Baseline (Visit 1/Week 1) to Visit 2 (Week 12) | The Full Analysis Set (FAS) included all subjects who had at least 1 valid Baseline and at least 1 valid post-Baseline efficacy measurement. | Scores on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Hand Grasp Speed Score | Baseline (Visit 1/Week 1) to Visit 2 (Week 12) | The Full Analysis Set (FAS) included all subjects who had at least 1 valid Baseline and at least 1 valid post-Baseline efficacy measurement. | Scores on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Hand Grasp Amplitude Score | Baseline (Visit 1/Week 1) to Visit 2 (Week 12) | The Full Analysis Set (FAS) included all subjects who had at least 1 valid Baseline and at least 1 valid post-Baseline efficacy measurement. | Scores on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Rapid Alternating Movement Speed Score | Baseline (Visit 1/Week 1) to Visit 2 (Week 12) | The Full Analysis Set (FAS) included all subjects who had at least 1 valid Baseline and at least 1 valid post-Baseline efficacy measurement. | Scores on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Rapid Alternating Amplitude Score | Baseline (Visit 1/Week 1) to Visit 2 (Week 12) | The Full Analysis Set (FAS) included all subjects who had at least 1 valid Baseline and at least 1 valid post-Baseline efficacy measurement. | Scores on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Change From Baseline to Visit 2 in Kinesia-ONE™ Variable: Dyskinesia Score | Baseline (Visit 1/Week 1) to Visit 2 (Week 12) | The Full Analysis Set (FAS) included all subjects who had at least 1 valid Baseline and at least 1 valid post-Baseline efficacy measurement. | Scores on a scale | LEAST_SQUARES_MEAN |
| PRIMARY | Neupro Dose Per 24h at Visit 2 (Week 12) | Visit 2 (Week 12) | The Full Analysis Set (FAS) included all subjects who had at least 1 valid Baseline and at least 1 valid post-Baseline efficacy measurement. | mg/24 hr | MEAN |
| PRIMARY | Number of Neupro Dose Changes During the Study | Visit 1 (Week 1) to Visit 2 (Week 12) | The Safety Set (SS) included all subjects who received at least 1 dose of Neupro. | dose changes | MEAN |
| PRIMARY | Number of Subjects Who Discontinued the Treatment With Neupro During the Course of the Study | Visit 1 (Week 1) to Visit 2 (Week 12) | The Safety Set (SS) included all subjects who received at least 1 dose of Neupro. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With Any Adverse Events During the Course of the Study | Visit 1 (Week 1) to Visit 2 (Week 12) | The Safety Set (SS) included all subjects who received at least 1 dose of Neupro. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03103919/outcomes